ASCRS 2023: Aurion clinical trials of endothelial cell therapy injection

Video

John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.

John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

John Berdahl, MD:

Hi, I'm John Berdahl here at ASCRS 2023. I'm a partner of Vance Thompson Vision and one of the investigators in the Aurion clinical trials of endothelial cell therapy injection.

I am an investigator and a consultant for them. So Aurion has now completed three clinical trials. The first one was done by Dr. Kinoshita in Japan, where this pioneering therapy was invented and then published in the New England Journal of Medicine and ultimately has a PMDA approval in Japan.

There have been two additional studies done in Central America that I was lucky to participate in alongside of colleagues Ed Holland, Liz Yeu, and Matt Giegengack. We went down to El Salvador, and we wiped off the endothelial cells, and we injected new cultured endothelial cells. And these were very sick eyes and the results were really remarkable. The average vision prior to injection was 22/100. When you take the average of all three studies, and that improved to 20/40. In really sick eyes, the average corneal thickness was about 700 microns. And that improved to about 550 microns on average across the three studies.

The safety thus far has been remarkable, and we're doing ongoing safety monitoring. And soon we'll be starting clinical trials here in the United States. So as I think about the technologies that are coming that could change how we treat our patients with corneal disease. This is at the forefront and I'm really excited to be able to participate in it.

Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.